Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

被引：0
|
作者：
T M Beer
D C Smith
A Hussain
M Alonso
J Wang
M Giurescu
K Roth
Y Wang
机构：
[1] Knight Cancer Institute,
[2] Oregon Health & Science University,undefined
[3] University of Michigan Health System,undefined
[4] University of Maryland Medical Center,undefined
[5] Marlene and Stewart Greenebaum Cancer Center,undefined
[6] Private Hospital of Córdoba,undefined
[7] University of Nebraska Medical Center,undefined
[8] Bayer HealthCare Pharmaceuticals,undefined
[9] Astellas Pharma Global Development,undefined
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
clinical trial; phase II; epothilones; prednisone; prostatic neoplasms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：808 / 813
页数：5
相关论文
共 50 条
  • [31] Activity of abiraterone acetate in metastatic patients with castration-resistant prostate cancer (mCRPC) previously treated with ketoconazole: A prospective phase II study from the prostate cancer clinical trials consortium
    Kim, Won
    Wilton, John
    Zhang, Li
    Lin, Amy M.
    Fong, Lawrence
    Friedlander, Terence W.
    Hsieh, Andrew Caleb
    Aggarwal, Rahul Raj
    Rodvelt, Tammy J.
    Morse, Allison
    Bozeman, Jeffrey
    Weinberg, Vivian K.
    Molina, Arturo
    Mohler, James
    Fetterly, Gerald J.
    Szmulewitz, Russell Zelig
    Small, Eric Jay
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [32] Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity
    Figg, William D.
    Chau, Cindy H.
    Madan, Ravi A.
    Gulley, James L.
    Gao, Rui
    Sissung, Tristan M.
    Spencer, Shawn
    Beatson, Melony
    Aragon-Ching, Jeanny
    Steinberg, Seth M.
    Dahut, William L.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 229 - 237
  • [33] Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Piera Federico
    Carmine D’Aniello
    Pasquale Rescigno
    Carla Cavaliere
    Livio Puglia
    Matteo Ferro
    Vincenzo Altieri
    Sisto Perdonà
    Sabino De Placido
    Giuseppe Di Lorenzo
    Cancer Chemotherapy and Pharmacology, 2011, 67 (6) : 1463 - 1463
  • [34] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
    Romero-Laorden, Nuria
    Lozano, Rebeca
    Jayaram, Anuradha
    Lopez-Campos, Fernando
    Saez, Maria, I
    Montesa, Alvaro
    Gutierrez-Pecharoman, Ana
    Villatoro, Rosa
    Herrera, Bernardo
    Correa, Raquel
    Rosero, Adriana
    Pacheco, Maria, I
    Garces, Teresa
    Cendon, Ylenia
    Paz Nombela, Ma
    Van de Poll, Floortje
    Grau, Gala
    Rivera, Leticia
    Lopez, Pedro P.
    Cruz, Juan-Jesus
    Lorente, David
    Attard, Gerhardt
    Castro, Elena
    Olmos, David
    BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1052 - 1059
  • [35] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
    Nuria Romero-Laorden
    Rebeca Lozano
    Anuradha Jayaram
    Fernando López-Campos
    Maria I. Saez
    Alvaro Montesa
    Ana Gutierrez-Pecharoman
    Rosa Villatoro
    Bernardo Herrera
    Raquel Correa
    Adriana Rosero
    María I. Pacheco
    Teresa Garcés
    Ylenia Cendón
    Ma Paz Nombela
    Floortje Van de Poll
    Gala Grau
    Leticia Rivera
    Pedro P. López
    Juan-Jesús Cruz
    David Lorente
    Gerhardt Attard
    Elena Castro
    David Olmos
    British Journal of Cancer, 2018, 119 : 1052 - 1059
  • [36] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    Dahut, William L.
    Madan, Ravi A.
    Karakunnel, Joyson J.
    Adelberg, David
    Gulley, James L.
    Turkbey, Ismail B.
    Chau, Cindy H.
    Spencer, Shawn D.
    Mulquin, Marcia
    Wright, John
    Parnes, Howard L.
    Steinberg, Seth M.
    Choyke, Peter L.
    Figg, William D.
    BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
  • [37] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
  • [38] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Hideyuki Akaza
    Hirotsugu Uemura
    Taiji Tsukamoto
    Seiichiro Ozono
    Osamu Ogawa
    Hideki Sakai
    Mototsugu Oya
    Mikio Namiki
    Satoshi Fukasawa
    Akito Yamaguchi
    Hiroji Uemura
    Yasuo Ohashi
    Hideki Maeda
    Atsushi Saito
    Kentaro Takeda
    Seiji Naito
    International Journal of Clinical Oncology, 2016, 21 : 773 - 782
  • [39] Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study
    Akaza, Hideyuki
    Ikemoto, Isao
    Namiki, Mikio
    Usami, Michiyuki
    Kobayashi, Mikio
    Fujimoto, Hiroyuki
    Tsukamoto, Taiji
    Naito, Seiji
    ONCOLOGY, 2010, 78 (5-6) : 323 - 328
  • [40] A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    Chi, K. N.
    Ellard, S. L.
    Hotte, S. J.
    Czaykowski, P.
    Moore, M.
    Ruether, J. D.
    Schell, A. J.
    Taylor, S.
    Hansen, C.
    Gauthier, I.
    Walsh, W.
    Seymour, L.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 746 - 751
12345